USV inaugurates injectables facility in India
This article was originally published in Scrip
USV of India has inaugurated its first sterile injectables facility in Daman, about 150kms from Mumbai. Set up with an investment of Rs500 million ($10.7 million), the new facility is equipped to handle a range of products involving recombinant proteins, peptides, small-molecule formulations and ophthalmic preparations. It has the capacity to produce 8.6 million vials on an annualised basis. The plant is also equipped with an ophthalmic formulation filling line and can produce more than five million vials. The new facility is expected to cater to the requirements of the US and European markets and USV expects to file for a FDA audit soon. USV, which is the leading manufacturer of metformin globally, is also developing a pipeline of biotechnology products and vaccines in India. It is developing vaccines for typhoid and hepatitis C and looking at in-licensing opportunities for vaccines for dengue and chikungunya, the company told Scrip earlier this year.